Dermata Therapeutics, Inc. (DRMA)

NASDAQ: DRMA · Delayed Price · USD
1.63
-0.10 (-5.52%)
At close: Jan 21, 2022 3:48 PM
1.59
-0.03 (-2.15%)
After-hours:Jan 21, 2022 4:36 PM EST
Market Cap13.53M
Revenue (ttm)n/a
Net Income (ttm)-8.31M
Shares Out8.33M
EPS (ttm)-3.09
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume167,537
Open1.66
Previous Close1.72
Day's Range1.53 - 1.69
52-Week Range1.41 - 6.95
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About DRMA

Dermata Therapeutics is a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions. Our Spongilla technology platform is based on the use of a naturally growing freshwater sponge, Spongilla lacustris, or Spongilla. Traditionally, locals would harvest the sponge to be used as a folk medicine to treat various inflammatory ailments, but research has been conducted to evaluate the use of Spongilla for the possible treatment of various skin diseases and aesthetic conditions. Our lead product candidate, ...

IndustryBiotechnology
IPO DateAug 13, 2021
CEOGerald T. Proehl
Employees7
Stock ExchangeNASDAQ
Ticker SymbolDRMA
Full Company Profile

Financial Performance

Financial Statements

News

Dermata Appoints Life Science Executive Brittany Bradrick to Board of Directors

SAN DIEGO, CA / ACCESSWIRE / January 13, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a clinical-stage biotechnology company focused on the treatment of medical and aes...

1 week ago - Accesswire

Dermata to Present at the H.C. Wainwright BioConnect Conference

SAN DIEGO, CA / ACCESSWIRE / January 5, 2022 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a clinical-stage biotechnology company focusing on the treatment of medical and aest...

2 weeks ago - Accesswire

Dermata's Aesthetic Improvement Candidate Fails To Impress - Read Why

Dermata Therapeutics Inc (NASDAQ: DRMA) announced data from its Phase 1b proof of concept study evaluating a single treatment of DMT410 to treat multiple aesthetic skin conditions. DMT410 showed improve...

2 months ago - Benzinga

Dermata Announces Positive Results from DMT410 Phase 1b Proof of Concept Study for Aesthetic Skin Conditions

Observed improvements in pore size, luminosity, brightness, and overall aesthetic appearance Duration of effect lasted approximately 3 months No potential distant spread of toxin observed SAN DIEGO, CA ...

2 months ago - Accesswire

Dermata Announces First Patient Enrolled in its Phase 2 Trial of DMT310 for the Treatment of Moderate-to-Severe Rosacea

Topline results expected in second half of 2022 Rosacea affects about 16 million patients in the U.S. SAN DIEGO, CA / ACCESSWIRE / November 17, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Comp...

2 months ago - Accesswire

Dermata Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Provides Corporate Update

- Announced positive topline results from DMT310 proof of concept (POC) study in mild-to-moderate psoriasis - - Closed upsized $18.0 million initial public offering (IPO) on Nasdaq Capital Market - - To...

2 months ago - Accesswire

Dermata Announces Presentation Details for Its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Socie...

SAN DIEGO, CA / ACCESSWIRE / November 12, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA), a clinical-stage biotechnology company focusing on the treatment of medical and a...

2 months ago - Accesswire

Dermata Announces Virtual Investor Event to Present DMT410 Phase 1b Proof of Concept Results in Aesthetic Skin Condit...

SAN DIEGO, CA / ACCESSWIRE / November 11, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA), a clinical-stage biotechnology company focusing on the treatment of medical and a...

2 months ago - Accesswire

Dermata Stock Jumps On Positive Psoriasis Candidate Data

Dermata Therapeutics Inc (NASDAQ: DRMA) announced topline results from its Phase 1b trial of DMT310 for mild-to-moderate psoriasis.  The percentage of treatment responders in Physician's Global Assessme...

3 months ago - Benzinga

Dermata Announces Positive Results from Phase 1b Clinical Trial of DMT310 for the Treatment of Mild-to-Moderate Psori...

- DMT310 achieved a PGA score of 0 or 1 for the target lesion in 29.6% of patients at Week 8 - - DMT310 demonstrated a total PASI score of 0 or 1 for the target lesion in 25.9% of patients at Week 8 - -...

3 months ago - Accesswire

Dermata Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Provides Corporate Update

- Completed oversubscribed $18 million Initial Public Offering (IPO) - - Set to announce topline results from its DMT310 Phase 1b proof of concept (POC) study in mild to moderate psoriasis in 4Q 2021 - ...

3 months ago - Accesswire

Top Penny Stocks To Buy The Dip According To Analysts In September

Analysts say these are penny stocks to buy right now. The post Top Penny Stocks To Buy The Dip According To Analysts In September appeared first on Penny Stocks to Buy, Picks, News and Information | Pen...

Other symbols:NMTRVSTMZYNE
3 months ago - PennyStocks

Why Are Dermata Therapeutics Shares Trading Higher Today?

Brookline has initiated Dermata Therapeutics Inc's (NASDAQ: DRMA) coverage with a Buy rating and $14 price target. Analyst Kumaraguru Raja sees an upside of almost 164%.

4 months ago - Benzinga

Dermata to Present Results from its DMT410 Phase 1b Proof of Concept Aesthetic Study at The American Society for Derm...

The presentation will highlight efficacy and safety data from a Phase 1b proof of concept study evaluating one application of DMT410 as a new topical intradermal delivery mechanism of botulinum toxin fo...

4 months ago - Accesswire

Dermata Therapeutics, Inc. Announces Appointment of Kyri Van Hoose as Senior Vice President, Chief Financial Officer

SAN DIEGO, CA / ACCESSWIRE / September 1, 2021 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (NASDAQ:DRMA)(NASDAQ:DRMAW), a clinical-stage biopharmaceutical company focused on the developme...

4 months ago - Accesswire

Dermata Therapeutics, Inc. Announces Closing of Upsized $18.0 Million Initial Public Offering

SAN DIEGO, CA / ACCESSWIRE / August 17, 2021 / Dermata Therapeutics, Inc. ("Dermata" or the "Company") (NASDAQ:DRMA, DRMAW), a clinical-stage medical dermatology company focused on identifying, developi...

5 months ago - Accesswire